[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NewAmsterdam Pharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100554219","phase-2-impact-of-obicetrapib-and-obicetrapib-plus-repatha-on-lpa-levels-100554219",false,"NCT06496243","Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels","A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study","VINCENT","Inclusion Criteria:\n\n* Lp(a): \\>=50 mg\u002FdL (\\>=125 nmol\u002FL) for cohort 1 (FILLED) and Lp(a) \\>= 20 mg\u002FdL (\\>= 50 nmol\u002FL) to \\\u003C50 mg\u002FdL (\\\u003C 125 nmol\u002FL) for cohort 2\n* LDL-C \\>70 mg\u002FdL\n* TG \\\u003C 400mg\u002FdL (\\\u003C4.52 mmol\u002FL)\n\nExclusion Criteria:\n\n* HbA1c\\>=10 or FPG \\>=270 mg\u002FdL\n* CV events within 3 months of screen","ALL","18 Years","75 Years",{"count":21,"type":22},69,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib\u002Fevolocumab\n\nPatients will:\n\nHave baseline Lp(a) tested at randomization Take 10mg\u002FdL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg\u002FdL obicetrapib daily\u002Fevolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16",[28],"Dyslipidemias","RECRUITING","2026-04-06",{"date":32,"type":33},"2026-04-09","ACTUAL",{"date":35,"type":33},"2024-12-02",{"date":37,"type":22},"2027-02",{"name":39,"class":40},"NewAmsterdam Pharma","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100609824","phase-3-a-study-to-evaluate-the-effect-of-obicetrapibezetimibe-10-mg-fixed-dose-combination-or-obicetrapib-10-mg-daily-on-top-of-guideline-recommended-lipid-lowering-therapy-in-participants-with-type-2-diabetes-andor-metabolic-syndrome-100609824","NCT07219602","A Study to Evaluate the Effect of Obicetrapib\u002FEzetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome","A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome (RUBENS Trial)","RUBENS","Inclusion Criteria:\n\n* fasting serum LDL-C ≥ 70 mg\u002FdL (≥1.81 mmol\u002FL)\n* Have fasting TG ≥150 mg\u002FdL (≥1.7 mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL)\n* Know diagnosis of T2DM OR have metabolic syndrome defined as fasting TG ≥150 mg\u002FdL (≥1.7mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL) and at least 2 risk factors\n* Are on stable guideline-recommended lipid-lowering therapy\n* Estimated glomerular filtration rate ≥15 mL\u002Fmin\u002F1.73 m2\n\nExclusion Criteria:\n\n* Have current or any previous history of New York Heart Association class III or IV heart failure or left ventricular ejection fraction \\\u003C30%\n* Have been hospitalized for heart failure within 5 years prior to Screening\n* Have uncontrolled severe hypertension\n* Have a formal diagnosis of homozygous familial hypercholesterolemia\n* HbA1c ≥10.0% (≥0.100 hemoglobin fraction) or a fasting glucose ≥270 mg\u002FdL (≥15.0 mmol\u002FL) at Screening\n* active liver disease",{"count":51,"type":22},300,[53],"PHASE3","This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and\u002For Type 2 Diabetes Mellitus.",[56,57,58],"Lipidemia","Type 2 Diabetes (T2DM)","Metabolic Syndrome (MetS)","2026-03-06",{"date":61,"type":33},"2026-03-10",{"date":63,"type":33},"2025-12-11",{"date":65,"type":22},"2028-06",{"name":39,"class":40},20,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":41},"100591598","phase-2-evaluation-of-obicetrapib-on-antioxidant-levels-in-plasma-and-hdl-particles-of-healthy-volunteers-100591598","NCT06982508","Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled Parallel Trial to Assess the Effects of Obicetrapib on Levels of Antioxidants in Plasma and HDL Particles in Healthy Volunteers: The VERMEER Study","VERMEER","Inclusion Criteria:\n\n* Visual acuity \\> 20\u002F60 in both eyes with or without corrective lenses\n\nExclusion Criteria:\n\n* Type 2 diabetes\n* Active liver disease\n* Any clinically significant macular pathology",true,{"count":78,"type":22},100,[25],"The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are:\n\nDo Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants.\n\nParticipants will:\n\nTake Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels",[82],"Antioxidant Absorption",[84],"Healthy Volunteer","2025-10-15",{"date":87,"type":33},"2025-10-20",{"date":89,"type":33},"2025-09-09",{"date":91,"type":22},"2026-12",{"name":39,"class":40},""]